A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes With Excess Blasts (MDS-EB), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Clofarabine (Primary) ; Fludarabine (Primary) ; Treosulfan (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 27 Sep 2023 Eligibility criteria amended to include subjects with 18 to 75 years of old.
- 31 May 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 26 May 2023 to 1 Jul 2023.
- 26 Apr 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 3 May 2023 to 26 May 2023.